2022 World Conference on Lung Cancer (ePosters)-EP08.02-144. The Impact of CNS Recurrence on Post-recurrence Survival in Patients with EGFR-mutation-positive Non-small-cell Lung Cancer

EP08.02-144. The Impact of CNS Recurrence on Post-recurrence Survival in Patients with EGFR-mutation-positive Non-small-cell Lung Cancer

Back to course

Pdf Summary

A study called KLSS-2 investigated the treatment and prognosis of postoperative recurrence in patients with EGFR-mutation positive non-small cell lung cancer. The study analyzed the data of 498 patients, out of which 340 had EGFR mutation assessed. The median survival time after recurrence was 31 months, and the 5-year survival rate was 32.1%. <br /><br />The study found that patients with CNS (central nervous system) recurrence were younger than those with non-CNS recurrence. However, there was no significant difference in prognosis between these two groups. Recurrence in multiple organs and recurrence of brain metastases were identified as independent poor prognostic factors after recurrence.<br /><br />In patients without EGFR mutation, CNS recurrence was associated with a poorer prognosis compared to non-CNS recurrence. However, in patients with EGFR mutation, there was no significant difference in prognosis between the two groups.<br /><br />The study suggests that the prevention of CNS recurrence after surgery may improve the post-recurrence prognosis in patients with EGFR-mutation positive lung cancer. It also highlights the potential benefit of adjuvant Osimertinib, which has been shown to prolong disease-free survival and reduce the risk of CNS recurrence in previous trials.<br /><br />In conclusion, the prognostic impact of CNS recurrence in patients with EGFR-mutation positive lung cancer remains unclear. Further research is needed to better understand and manage CNS recurrence in this patient population.

Asset Subtitle

Tatsuro Okamoto

Meta Tag

Speaker Tatsuro Okamoto

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

KLSS-2

postoperative recurrence

EGFR-mutation positive lung cancer

prognosis

CNS recurrence

non-CNS recurrence

brain metastases

patients without EGFR mutation

patients with EGFR mutation

adjuvant Osimertinib